News Releases
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
January 5, 2021- Management Provides Update on Timing of Data for IMU-838 in Primary Sclerosing Cholangitis -
-
December 14, 2020
-
November 24, 2020
-
November 17, 2020- Initial Appointments Include Internationally Recognized Experts: Fred D. Lublin, M.D.; Bruce E. Sands, M.D., M.S.; Jerrold R. Turner, M.D., Ph.D. and Paul J. Utz, M.D. -
-
November 5, 2020- Released Very Positive Phase 2 Data for IMU-838 in Relapsing-Remitting Multiple Sclerosis; Company to Submit End-of-Phase 2 Meeting Requests to Regulatory Authorities at the End of Q1 2021 -
-
November 2, 2020- Top-Line Data Expected in Q1 2021 -
-
October 20, 2020- European Investment Bank and Immunic sign a financing agreement of up to €24.5 million to support the development of Immunic's lead asset, IMU-838, in moderate COVID-19
-
September 29, 2020
-
September 11, 2020- Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations -
-
August 2, 2020- Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis -
-
July 27, 2020- Study Being Conducted in Collaboration with University Hospitals Coventry and Warwickshire NHS Trust -
-
June 22, 2020
-
May 19, 2020- Presentation Will Include Preclinical Data of IMU-838 Against SARS-CoV-2 as Well as First Pharmacokinetic Data From the Ongoing Phase 1 Clinical Trial of IMU-935 -
-
April 23, 2020
-
April 21, 2020- In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 -
-
April 17, 2020
-
March 16, 2020- Top-Line Data from Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Expected in Third Quarter 2020 -
-
January 8, 2020Phase 1 Clinical Studies to begin in First Half of 2020
-
December 4, 2019IMU-856 has the potential to address one of the putative root causes of inflammatory bowel disease without impairing the immune system
-
October 10, 2019- Milestone Achieved Nine Months Ahead of Initial Schedule; Top-Line Data Expected in Q3 2020 -
-
September 11, 2019Preclinical Findings Confirm Favorable Profile of IMU-838 as Compared to Teriflunomide in the Potential Treatment of Relapsing-Remitting Multiple Sclerosis
-
September 5, 2019- Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dose -
-
August 12, 2019- Study Being Conducted in Collaboration with Investigators at Arizona State University and the Mayo Clinic -